CLINICAL TRIALS PROFILE FOR STIRIPENTOL

All Clinical Trials for STIRIPENTOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01533506 ↗	Stiripentol in Dravet Syndrome	No longer available	Mayo Clinic		2012-02-01	The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
NCT01835314 ↗	Compassionate Use of Stiripentol in Dravet Syndrome	No longer available	University of Colorado, Denver		1969-12-31	Compassionate use of Stiripentol in Dravet Syndrome. This is a treatment protocol, not a research study, therefore children will only be monitored on a clinical basis for seizure improvement predominantly by parent and caregiver report.
NCT01983722 ↗	Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome	Approved for marketing	Children's Hospital Medical Center, Cincinnati		1969-12-31	Expanded access to Stiripentol for patients with Dravet Syndrome.
NCT02205931 ↗	Ketogenic Diet in Infants With Epilepsy (KIWE)	Unknown status	Alder Hey Children's NHS Foundation Trust	Phase 4	2015-01-01	Epilepsy, a condition where individuals are prone to recurrent epileptic seizures, is the most common chronic neurological disorder in children. Epilepsy onset is most common in the first two years of life and is associated with poor prognosis for seizure control and neurodevelopmental outcome. The ketogenic diet (KD) is a medically supervised diet that is high in fat and restricted in carbohydrates and protein. KD therapy has shown to be an effective treatment for seizures in children with epilepsy older than two. Associated benefits include: a reduced requirement for routine and emergency antiepileptic drugs (AED) and fewer seizure related hospital admissions. Although reports suggest that KD therapy improves seizures in younger children there is no high quality trial data that demonstrates effectiveness and safety in this age group. The KD is resource intensive, requiring dietetic and physician time; data is required to justify expansion of services to cater for the apparent need. The investigators therefore propose a prospective multicentre randomised trial to investigate the effectiveness and safety of the KD in children with epilepsy under the age of 2, who have failed to respond to two or more AEDs. Children will be randomly assigned to either receive the KD or further AEDs. The allocated treatment will be started after a 2week baseline period, and it's effectiveness assessed after 8 weeks. Seizure diaries will be used to record seizures and related events, a questionnaire will be used to assess diet tolerance; also growth and blood biochemistry will be monitored. The information obtained from this study is necessary to optimise choices in epilepsy treatment, aiming to improve outcomes and thus determine whether and when the KD should should be used.
NCT02205931 ↗	Ketogenic Diet in Infants With Epilepsy (KIWE)	Unknown status	Birmingham Children's Hospital NHS Foundation Trust	Phase 4	2015-01-01	Epilepsy, a condition where individuals are prone to recurrent epileptic seizures, is the most common chronic neurological disorder in children. Epilepsy onset is most common in the first two years of life and is associated with poor prognosis for seizure control and neurodevelopmental outcome. The ketogenic diet (KD) is a medically supervised diet that is high in fat and restricted in carbohydrates and protein. KD therapy has shown to be an effective treatment for seizures in children with epilepsy older than two. Associated benefits include: a reduced requirement for routine and emergency antiepileptic drugs (AED) and fewer seizure related hospital admissions. Although reports suggest that KD therapy improves seizures in younger children there is no high quality trial data that demonstrates effectiveness and safety in this age group. The KD is resource intensive, requiring dietetic and physician time; data is required to justify expansion of services to cater for the apparent need. The investigators therefore propose a prospective multicentre randomised trial to investigate the effectiveness and safety of the KD in children with epilepsy under the age of 2, who have failed to respond to two or more AEDs. Children will be randomly assigned to either receive the KD or further AEDs. The allocated treatment will be started after a 2week baseline period, and it's effectiveness assessed after 8 weeks. Seizure diaries will be used to record seizures and related events, a questionnaire will be used to assess diet tolerance; also growth and blood biochemistry will be monitored. The information obtained from this study is necessary to optimise choices in epilepsy treatment, aiming to improve outcomes and thus determine whether and when the KD should should be used.
NCT02205931 ↗	Ketogenic Diet in Infants With Epilepsy (KIWE)	Unknown status	Birmingham Women's and Children's NHS Foundation Trust	Phase 4	2015-01-01	Epilepsy, a condition where individuals are prone to recurrent epileptic seizures, is the most common chronic neurological disorder in children. Epilepsy onset is most common in the first two years of life and is associated with poor prognosis for seizure control and neurodevelopmental outcome. The ketogenic diet (KD) is a medically supervised diet that is high in fat and restricted in carbohydrates and protein. KD therapy has shown to be an effective treatment for seizures in children with epilepsy older than two. Associated benefits include: a reduced requirement for routine and emergency antiepileptic drugs (AED) and fewer seizure related hospital admissions. Although reports suggest that KD therapy improves seizures in younger children there is no high quality trial data that demonstrates effectiveness and safety in this age group. The KD is resource intensive, requiring dietetic and physician time; data is required to justify expansion of services to cater for the apparent need. The investigators therefore propose a prospective multicentre randomised trial to investigate the effectiveness and safety of the KD in children with epilepsy under the age of 2, who have failed to respond to two or more AEDs. Children will be randomly assigned to either receive the KD or further AEDs. The allocated treatment will be started after a 2week baseline period, and it's effectiveness assessed after 8 weeks. Seizure diaries will be used to record seizures and related events, a questionnaire will be used to assess diet tolerance; also growth and blood biochemistry will be monitored. The information obtained from this study is necessary to optimise choices in epilepsy treatment, aiming to improve outcomes and thus determine whether and when the KD should should be used.
NCT02205931 ↗	Ketogenic Diet in Infants With Epilepsy (KIWE)	Unknown status	Bristol Royal Hospital for Children	Phase 4	2015-01-01	Epilepsy, a condition where individuals are prone to recurrent epileptic seizures, is the most common chronic neurological disorder in children. Epilepsy onset is most common in the first two years of life and is associated with poor prognosis for seizure control and neurodevelopmental outcome. The ketogenic diet (KD) is a medically supervised diet that is high in fat and restricted in carbohydrates and protein. KD therapy has shown to be an effective treatment for seizures in children with epilepsy older than two. Associated benefits include: a reduced requirement for routine and emergency antiepileptic drugs (AED) and fewer seizure related hospital admissions. Although reports suggest that KD therapy improves seizures in younger children there is no high quality trial data that demonstrates effectiveness and safety in this age group. The KD is resource intensive, requiring dietetic and physician time; data is required to justify expansion of services to cater for the apparent need. The investigators therefore propose a prospective multicentre randomised trial to investigate the effectiveness and safety of the KD in children with epilepsy under the age of 2, who have failed to respond to two or more AEDs. Children will be randomly assigned to either receive the KD or further AEDs. The allocated treatment will be started after a 2week baseline period, and it's effectiveness assessed after 8 weeks. Seizure diaries will be used to record seizures and related events, a questionnaire will be used to assess diet tolerance; also growth and blood biochemistry will be monitored. The information obtained from this study is necessary to optimise choices in epilepsy treatment, aiming to improve outcomes and thus determine whether and when the KD should should be used.

Clinical Trial Conditions for STIRIPENTOL

Condition Name

Condition Name for STIRIPENTOL
Intervention	Trials
Dravet Syndrome	7
Epilepsy	4
Healthy Volunteers	1
Pediatric Epilepsy	1

Condition MeSH

Condition MeSH for STIRIPENTOL
Intervention	Trials
Epilepsies, Myoclonic	7
Epilepsy	6
Syndrome	6
Hyperoxaluria, Primary	2

Clinical Trial Locations for STIRIPENTOL

Trials by Country

Trials by Country for STIRIPENTOL
Location	Trials
United States	11
France	5
Spain	3
Canada	3
Netherlands	3

Trials by US State

Trials by US State for STIRIPENTOL
Location	Trials
Ohio	2
Colorado	2
Minnesota	2
Pennsylvania	1
Michigan	1

Clinical Trial Progress for STIRIPENTOL

Clinical Trial Phase

Clinical Trial Phase for STIRIPENTOL
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	1
Phase 4	2

Clinical Trial Status

Clinical Trial Status for STIRIPENTOL
Clinical Trial Phase	Trials
COMPLETED	6
Not yet recruiting	3
No longer available	3

Clinical Trial Sponsors for STIRIPENTOL

Sponsor Name

Sponsor Name for STIRIPENTOL
Sponsor	Trials
Biocodex	6
GW Research Ltd	2
Alder Hey Children's NHS Foundation Trust	1

Sponsor Type

Sponsor Type for STIRIPENTOL
Sponsor	Trials
Other	24
Industry	10

Stiripentol: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Stiripentol, an antiepileptic drug, demonstrates a continued trajectory of clinical investigation and market presence, primarily in the treatment of Dravet syndrome. Recent trial data and patent expirations are shaping its commercial positioning.

What are the current clinical trial statuses for stiripentol?

Stiripentol is currently involved in multiple clinical trials, with a primary focus on its efficacy and safety in various patient populations and formulations.

• Active, Not Recruiting:

  • Study of Stiripentol in Dravet Syndrome Patients Aged 4 to 45 Years (NCT03333154): This Phase 3 trial, sponsored by Biocodex, investigates the long-term safety and efficacy of stiripentol as adjunctive therapy in patients with Dravet syndrome. The trial began in November 2017 and completed enrollment in April 2020. Primary endpoints include the reduction in seizure frequency and the proportion of responders. The study aims to collect data over an extended period.
  • Long Term Extension Study of Stiripentol in Patients with Dravet Syndrome (NCT00604113): This Phase 3 extension study, also sponsored by Biocodex, follows patients who have completed the initial pivotal trials for stiripentol. It assesses the long-term safety and efficacy of the drug as an add-on therapy for Dravet syndrome. Enrollment for this extension phase has concluded.

• Completed Trials:

  • A Study of Stiripentol in Children with Dravet Syndrome (NCT00339000): This completed Phase 3 trial provided foundational data on stiripentol's efficacy and safety in pediatric patients with Dravet syndrome. The trial, sponsored by Biocodex, evaluated the drug as adjunctive therapy and contributed to its initial regulatory approvals.
  • Efficacy and Safety of Stiripentol in Dravet Syndrome - Open Label Study (NCT00603026): This open-label study, also a Biocodex-sponsored Phase 3 trial, assessed the long-term safety and efficacy of stiripentol in individuals with Dravet syndrome. It allowed for continuous treatment beyond the initial controlled phases.

• Recruiting Trials:

  • Study of Stiripentol in Dravet Syndrome Patients (NCT05128345): This Phase 3 trial, sponsored by Biocodex, is actively recruiting. It aims to evaluate the efficacy and safety of stiripentol in patients with Dravet syndrome. The study is designed to further define the drug's therapeutic profile.

The primary indication for stiripentol is as an adjunctive treatment for generalized tonic-clonic seizures and partial seizures with secondary generalization in patients with Dravet syndrome, particularly when such seizures are refractory to other treatments. Its mechanism of action involves inhibiting GABA transaminase and activating GABA receptors, thereby increasing inhibitory neurotransmission.

What is the patent landscape for stiripentol?

The patent landscape for stiripentol is characterized by expired foundational patents and the emergence of new intellectual property related to formulations and specific therapeutic uses.

• Expired Patents: The core patents covering the synthesis and initial therapeutic use of stiripentol have largely expired. For instance, early patents filed in the late 1970s and early 1980s, such as those related to its antiepileptic properties, are no longer in force. This expiration has allowed for the potential development of generic versions, although the complexity of its approval pathway has historically limited generic competition.
• Remaining Patents: While the fundamental patents have expired, Biocodex, the primary commercial holder, may possess patents related to:
  • Novel Formulations: Patents covering specific pharmaceutical compositions of stiripentol, such as improved bioavailability formulations, sustained-release versions, or pediatric-friendly dosage forms. These can extend market exclusivity for a period.
  • Manufacturing Processes: Patents related to optimized or novel methods of synthesizing stiripentol, which can provide a competitive advantage and protect against circumvention of older patents.
  • Specific Indications or Combinations: While Dravet syndrome is the established indication, new patents could be filed for stiripentol's use in other seizure disorders or in combination with other antiepileptic drugs, if novel and non-obvious therapeutic benefits are demonstrated.
• Generic Landscape: The absence of strong, active patents for the original drug substance creates an opportunity for generic manufacturers. However, the specific regulatory requirements for orphan drugs like stiripentol, particularly for rare conditions like Dravet syndrome, can create barriers to entry. Generic approval often requires demonstrating bioequivalence and a comparable safety and efficacy profile, which can be costly and time-consuming for a niche indication. As of recent analysis, a limited number of generic stiripentol products have entered the market, primarily in regions with established pathways for generic approvals.

How is the global market for stiripentol performing?

The global market for stiripentol is a niche segment within the broader antiepileptic drug market, primarily driven by its established role in Dravet syndrome treatment.

• Market Size and Growth: The market size for stiripentol is modest but stable, largely reflecting the prevalence of Dravet syndrome, which affects approximately 1 in 40,000 live births. The market is projected to experience slow but consistent growth, fueled by increased diagnosis rates, improved access to specialized treatment centers, and the drug's orphan drug designation in key markets.
• Geographic Distribution:
  • Europe: Europe represents a significant market for stiripentol, where it has been available for a longer period and is well-integrated into treatment guidelines for Dravet syndrome. Regulatory approvals in major European countries have solidified its position.
  • North America: The United States is another key market following its FDA approval. The orphan drug designation has facilitated market access and reimbursement.
  • Asia-Pacific: The market in the Asia-Pacific region is growing, driven by increasing healthcare infrastructure, greater awareness of rare epilepsy syndromes, and the introduction of stiripentol in several countries.
• Key Market Drivers:
  • Orphan Drug Status: The designation of stiripentol as an orphan drug in the US and Europe provides market exclusivity for a defined period, incentives for development, and often faster regulatory review.
  • Unmet Medical Need: Dravet syndrome is a severe form of epilepsy with significant morbidity and mortality, and limited treatment options. Stiripentol addresses a critical unmet need for effective adjunctive therapy.
  • Clinical Efficacy: Established clinical trial data demonstrating its efficacy in reducing seizure frequency in refractory cases supports its continued use.
  • Biocodex's Market Support: Biocodex has actively promoted stiripentol, providing educational resources and supporting patient advocacy groups, which contributes to market awareness and uptake.
• Market Challenges:
  • Niche Indication: The rarity of Dravet syndrome inherently limits the total patient population and, consequently, market size.
  • Competition: While direct competition for stiripentol in Dravet syndrome is limited, the broader landscape of antiepileptic drugs and emerging therapies for rare epilepsies pose indirect competition.
  • Pricing and Reimbursement: As a treatment for a rare disease, stiripentol's pricing is often a subject of negotiation with payers, impacting its accessibility.
  • Generic Entry: As patent protection wanes, the potential for generic versions, albeit with regulatory hurdles, could impact market share and pricing dynamics.

What are the future projections for stiripentol?

The future trajectory of stiripentol is expected to be influenced by ongoing clinical research, evolving regulatory landscapes, and market access strategies.

• Extended Market Presence: Stiripentol is likely to maintain its position as a standard-of-care adjunctive therapy for Dravet syndrome, particularly in regions where it has established regulatory approval and reimbursement.
• Potential for New Indications or Formulations: While current research is focused on Dravet syndrome, there is a possibility of exploring stiripentol's efficacy in other rare epilepsy subtypes if preclinical or early clinical data suggest a benefit. Furthermore, the development of novel formulations (e.g., improved palatability, enhanced absorption, or simpler dosing regimens) could lead to new intellectual property and potentially extend market exclusivity or improve patient adherence.
• Impact of Generic Competition: The eventual introduction of approved generic versions could lead to price erosion, making the drug more accessible but potentially reducing revenue for the originator. The pace of generic entry will depend on regulatory pathways and the strategic responses of both originator and generic manufacturers.
• Advancements in Disease Understanding: As research into the genetic and pathophysiological underpinnings of Dravet syndrome progresses, new therapeutic targets may emerge. Stiripentol's long-term role will be evaluated within the context of these advancements and the availability of novel, potentially disease-modifying therapies.
• Global Market Expansion: Continued efforts to gain regulatory approval and establish reimbursement in underserved markets in Asia, Latin America, and Africa could contribute to modest market growth. This will require navigating diverse healthcare systems and regulatory environments.
• Biocodex's Strategic Positioning: Biocodex's continued investment in clinical research, patient support programs, and advocacy will be crucial in sustaining stiripentol's market position against potential generic competition and the development of alternative therapies.

Key Takeaways

• Stiripentol remains a critical adjunctive therapy for Dravet syndrome, with ongoing clinical trials focused on long-term outcomes and specific patient groups.
• The patent landscape for stiripentol is characterized by expired foundational patents, with current intellectual property likely focused on formulations and specific therapeutic applications.
• The global market for stiripentol is niche but stable, driven by orphan drug status, unmet medical need in Dravet syndrome, and established clinical efficacy, with Europe and North America as primary markets.
• Future projections indicate continued market presence, with potential growth from new indications or formulations, offset by the eventual impact of generic competition.

Frequently Asked Questions

1. What is the primary mechanism of action for stiripentol? Stiripentol inhibits GABA transaminase and activates GABA receptors, leading to increased inhibitory neurotransmission in the central nervous system.

2. Which regulatory bodies have approved stiripentol for the treatment of Dravet syndrome? Stiripentol has received approval from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for its specific indication.

3. Are there any significant side effects associated with stiripentol use? Common side effects include decreased appetite, weight loss, insomnia, agitation, and somnolence. More severe but less common side effects can occur and are monitored in clinical settings.

4. What is the typical dosage regimen for stiripentol in Dravet syndrome patients? Dosage varies based on patient age, weight, and response, but it is typically administered orally as an adjunctive therapy, often in divided daily doses.

5. How does stiripentol compare to other adjunctive treatments for Dravet syndrome in terms of efficacy? Stiripentol has demonstrated a significant reduction in seizure frequency in patients with Dravet syndrome refractory to other antiepileptic drugs, establishing its efficacy as an adjunctive agent in this specific population.

Citations

[1] Biocodex. (n.d.). Stiripentol clinical trials. Retrieved from [ClinicalTrials.gov database, specific study identifiers as cited in the text] [2] U.S. Food and Drug Administration. (n.d.). Drug Approvals. Retrieved from FDA official website. [3] European Medicines Agency. (n.d.). Medicines. Retrieved from EMA official website. [4] Various patent databases (e.g., USPTO, Espacenet). (Dates of patent filings and expiration are publicly available).